Ugonin L inhibits osteoclast formation and promotes osteoclast apoptosis by inhibiting the MAPK and NF-κB pathways

Chun-Lin Liu; Trung-Loc Ho; Shuen-Yih Fang; Jeng-Hung Guo; Chih-Ying Wu; Yi-Chin Fong; Chih-Chuang Liaw; Chih-Hsin Tang

doi:10.1016/j.biopha.2023.115392

Ugonin L inhibits osteoclast formation and promotes osteoclast apoptosis by inhibiting the MAPK and NF-κB pathways

Biomed Pharmacother. 2023 Oct:166:115392. doi: 10.1016/j.biopha.2023.115392. Epub 2023 Aug 29.

Authors

Chun-Lin Liu¹, Trung-Loc Ho², Shuen-Yih Fang³, Jeng-Hung Guo¹, Chih-Ying Wu⁴, Yi-Chin Fong⁵, Chih-Chuang Liaw⁶, Chih-Hsin Tang⁷

Affiliations

¹ Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
² Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
³ Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung, Taiwan.
⁴ Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taiwan; Department of Neurosurgery, China Medical University Hsinchu Hospital, Hsinchu, Taiwan.
⁵ Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Beigang Hospital, Yunlin, Taiwan.
⁶ Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung, Taiwan; Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: ccliaw@mail.nsysu.edu.tw.
⁷ Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan; Chinese Medicine Research Center, China Medical University, Taichung, Taiwan; Department of Medical Laboratory Science and Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan; Department of Medical Research, China Medical University Hsinchu Hospital, Hsinchu, Taiwan. Electronic address: chtang@mail.cmu.edu.tw.

PMID: 37651802
DOI: 10.1016/j.biopha.2023.115392

Abstract

Bone loss is a major issue for patients with osteoporosis, arthritis, periodontitis, and bone metastasis; however, anti-resorption drugs used to treat bone loss have been linked to a variety of adverse effects. Helminthostachys zeylanica (L.) Hook, belonging to the family Ophioglossaceae, is commonly used in traditional Chinese medicine to treat inflammation and liver problems. In the current study, ugonin L extracted from H. zeylanica was shown to reduce the receptor activator of nuclear factor kappa beta ligand (RANKL)-induced osteoclastogenesis in RAW264.7 cells in a concentration-dependent manner. Ugonin L treatment also inhibited the mRNA expression of osteoclast markers. Ugonin L was also shown to promote cell apoptosis in mature osteoclasts and suppress RANKL-induced ERK, p38, JNK, and NF-κB activation. Taken together, ugonin L appears to be a promising candidate for the development of novel anti-resorption therapies.

Keywords: Apoptosis; Bone resorption; Osteoclast; RANKL; Ugonin L.

MeSH terms

Apoptosis
Bone Diseases, Metabolic*
Drugs, Chinese Herbal / pharmacology
Humans
NF-kappa B*
Osteoclasts / drug effects
Osteoclasts / metabolism
Osteogenesis
RANK Ligand / drug effects
RANK Ligand / metabolism
Signal Transduction

Substances

NF-kappa B
Drugs, Chinese Herbal
RANK Ligand